Reuters
New Delhi: Vaccine and drug maker Panacea Biotec Ltd expects to get World Health Organisation’s (WHO) pre-qualification for its pentavalent combination vaccine in July-Sept quarter, its joint managing director said.
Pre-qualification acts as a guide to help countries and United Nations agencies select suppliers for the drugs.
“With only two players and both not able to meet the market demand, I think there is a huge opportunity lying in front of us,” Rajesh Jain told Reuters.
“It is a market of close to 120 million doses per year and market size of $350-400 million,” he added.
Panacea’s Easyfive is a combination of vaccines for immunising children against Hepatitis B, diphtheria, tetanus etc.
The firm was pre-qualified by WHO in January to supply two other combination vaccines for paediatric immunisation.